NMPA quasi-anti-anti-anti-inflammatory drug Cimzia (Pesseli-pearl monoantigen) used to treat patients with rheumatoid arthritis

The NationalPharmaceutical(http://Regulatory Authority (NMPA) has approved the anti-inflammatory drug Cimzia (certolizumab pegol, pisserizumab single anti-injection) for treatment of patients with moderate to severe rheumatoid arthritis (RA), the belgianPharmaceutical(http://giant UCB announcedAbout Cimzia
Cimzia is a fc-free, polyglycol-modified anti-tumor necrosis factor alpha (TNF-alpha)drug(http://, has a very high affinity for human TNF-alpha, and is able to selectively and tNF-alpha."To date, Cimzia has been approved by many countries and regions around the world for the treatment of a variety of inflammatory diseases, including rheumatoid arthritis, psoriasis arthritis, stoic syllritis, spinal arthritis, Crohn's disease, etcAt the end of March 2019, Cimzia was approved by the u.SFDA (http:// a new indication for the treatment of adult patients with active non-radiative hypercopteriade (nr-axSpA) with inflammatory signs 　　The study the submission of Cimzia's listing application, based on data from two Phase III Clinical Trial (http:// RAPID-C and RAPID-C Open Label (OLE) The two trials were conducted in adult sequoia-to-severe active RA patients who had previously under-responded to methotrexate (MTX), assessing the efficacy and safety of Cimzia-combined MTX 　　The results showed that the combination of Cimzia and MTX showed rapid and consistent efficacy in reducing RA signs and symptoms, improving body function, and had acceptable safety compared to single MTX Uber also included specific pregnancy and lactation information in its listing application, based on the results of two first studies of its kind in women of childbearing age, and data on pregnancy outcomes